Glucagon Research

Qiao Y, Zhou F, Mao T, Gao L

Glucose-dependent insulinotropic polypeptide (GIP), once the overlooked sibling of the incretin family, is now experiencing a research renaissance. Historically, its therapeutic development was hindered by a seemingly diminished insulinotropic effect in type 2 diabetes (T2DM), its paradoxical sti...

Wang MJ, Jiang YN, Li PP, Wu YJ

Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of chronic liver disease globally, with limited treatment options. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show potential for MASH due to their metabolic benefits, but evidence on histological outcomes remain...

Chen Q, Chen T, Lin W, Chen X

To conduct a systematic, multi-dimensional clinical evaluation of five long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) available in China, providing evidence-based guidance for clinical preference and institutional formulary selection.This study was structured according to the "A...

Razmi S, Moshtaghie AA, Seyedabadi M, Hashem N, Akbarzadeh S

Exercise-induced ionic changes can modulate the interaction between liraglutide and the glucagon-like peptide-1 receptor (GLP-1R). To investigate this, molecular dynamics simulations and in vivo experiments using streptozotocin-induced diabetic rats were performed. Under exercise-mimicking ionic ...

Wen A, Jiao Y, Wang N, Xu J, Xu X, Du L et al.

This study aimed to explore intervention strategies for fluid and electrolyte regulation in patients with high-output stomas, to optimize their clinical outcomes and quality of life.Fifteen experimental and semi-experimental studies were systematically reviewed. Interventions were categorized int...

Su C, Cui Z, Guo J

Cerebral small vessel disease (CSVD) is a leading cause of stroke and vascular cognitive impairment, but its metabolic determinants are not fully understood. Emerging evidence indicates that insulin resistance (IR) plays a crucial role in CSVD through vascular, inflammatory, and oxidative mechani...

Schaefer LM, Kerver GA, Allison KC, Kohoutek B, Steffen KJ

Limited available data indicate that glucagon-like peptide-1 (GLP-1) medications may significantly reduce weight and binge-eating symptoms among patients with binge-eating disorder. However, experts express concern about the potential for GLP-1 medications to cause unintended harm or be misused a...

Warden BA, Duell PB, Bucheit JD, Purnell JQ

Obesity is a chronic disease, rooted in genetic predisposition and homoeostatic counter-regulatory adaptive and hormonal responses, with escalating prevalence rates and numerous associated health consequences.Historically, interventions beyond lifestyle for the treatment of obesity have been unde...

Landry MJ, Bagha Z

Lifestyle modification remains the cornerstone of obesity management, serving as an essential component of all treatment plans, even in an era of effective pharmacotherapy.This review examines the key elements of lifestyle interventions, their mechanisms of action, implementation strategies, and ...

Smith BL, May A, Lalani F, Hasham S, Presnell AA

Obesity is a chronic, multifactorial disease associated with significant metabolic, physical, and psychosocial complications. Although advances in pharmacologic therapy-particularly glucagon-like peptide-1 (GLP-1)-based agents-have expanded treatment options, challenges persist in the effective m...

Narla S, Narla RR, Corbett JA

The prevalence of obesity and type 2 diabetes mellitus (T2DM) continues to rise in the United States (U.S.) and worldwide, contributing to substantial morbidity and mortality through metabolic dysfunction and systemic inflammation. Glucagon-like peptide-1(GLP-1)-based therapies, originally develo...

Dao MQ, Kim AY, Wang S, Won P, Laspro M, Gillenwater TJ et al.

Avogaro A, Neccia M, Delfini M, Franculli A, Enea G, Magli A et al.

Rose BD, Kreuch D, Wu T, Horowitz M, Rayner CK, Page AJ et al.

Foods and beverages sweetened with non-nutritive sweeteners (NNSs) are increasingly common in modern diets and widely promoted as healthy alternatives to their sugar-sweetened counterparts, with attendant benefits for individuals with preclinical or clinical metabolic disease. Despite this positi...

Ando K, Takenoshita M, Wei MT

A 58-year-old man scheduled for an elective upper endoscopy followed standard preprocedural fasting guidelines and withheld one weekly dose of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA). Despite these measures, substantial residual gastric contents led to procedure...

Leong D, Gong S, Sattar N, Narayan V, Reizine NM, Gerstein H et al.

Incretin mimetics (glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists) are paradigm changing for managing obesity, diabetes, and cardiovascular risk. These phenotypes are also associated with elevated risk for ...

Fountoulakis N, Pavlou P, Stathi D, Goubar A, Corcillo A, Flaquer M et al.

People with chronic kidney disease (CKD) and diabetes are at high risk of cardiovascular disease (CVD). Aortic pulse wave velocity (Ao-PWV) is an independent predictor of CVD. Cardiovascular outcome trials (CVOTs) with glucagon like peptide-1 receptor agonist (GLP-1 RA) class demonstrate notable ...

Graczyk NA, Bisschops J

The effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in menopausal and postmenopausal women are not well characterized and may differ from other patient populations, given their different hormone profiles. Current research evaluating the effects of GLP-1RAs on weight loss, cardiova...

Makkena HB

Background The rapid adoption of incretin-based therapies for obesity has raised questions regarding their comparative safety profiles. While the gynecological safety of glucagon-like peptide-1 (GLP-1) receptor agonists is documented, the potential risks associated with dual glucose-dependent ins...

Rubino DM, Mooney V, van de Walle V, Baanstra D, Daniëls W, Recaldin C et al.

Clinical trial simulations (CTSs) are an increasingly common way to incorporate site staff and participant feedback into clinical trial design. CTSs can help overcome the unique challenges presented in obesity trials. Here, a CTS was conducted for three trials from the SYNCHRONIZE™ phase 3...